Desai, A. S., Vardeny, O., Claggett, B., McMurray, J. J. V., Packer, M., Swedberg, K., … Solomon, S. D. (2017). Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2(1), 79–79. https://doi.org/10.1001/jamacardio.2016.4733

Desai, Akshay S., Orly Vardeny, Brian Claggett, John J. V. McMurray, Milton Packer, Karl Swedberg, Jean L. Rouleau, et al. “Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril.” JAMA Cardiology 2, no. 1 (January 1, 2017): 79–79. https://doi.org/10.1001/jamacardio.2016.4733.

Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology. 2017 Jan 1;2(1):79–79.

Desai, Akshay S., et al. “Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril.” JAMA Cardiology, vol. 2, no. 1, American Medical Association (AMA), Jan. 2017, pp. 79–79. Crossref, doi:10.1001/jamacardio.2016.4733.

Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology. American Medical Association (AMA); 2017 Jan 1;2(1):79–79.